Company Dossier · Health Care
Dexcom
- S&P 500
- Nasdaq-100
- Russell 1000
What Dexcom is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $4.97 billion, up 16% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $1.41 billion, up 147% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.34 billion, down 19% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.50 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 30, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
- Guidance in the last 90 days: 4 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 12, 2026): 1 risk factor added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $8.7 million on the open market.SEC Form 4
- 978 institutional managers reported a position at June 30, 2026 (+16 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 23 (23 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Dexcom is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Confident
Expanding ↔ Retrenching
Steady
- Capital spending26th pct
- Debt raised—
- Buybacks vs capex—
- Hiring filings74th pct
- Deals and private raises49th pct
- Patent publications32nd pct
Confident ↔ Hedging
Confident
- Call sentiment89th pct
- Call confidence88th pct
- Guidance changes97th pct
- Risk factors added50th pct
- Insider open-market trades38th pct
- + Guidance changes
- + Call sentiment
- + Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver73rd pct
- Stress filings36th pct
Credit
How these are built →No bond term sheets or tagged debt on file for Dexcom yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Dexcom: earnings call confidence
Palanor Discourse score per call, 0 to 1
Hiring and ownership
In the news
Headlines that name Dexcom, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralDexCom gains after NEJM data on insulin pump (DXCM:NASDAQ)
seekingalpha.com · via Marketaux · Oct 15, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (FARRAGUT PARTNERS LLP)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (DEXCOM, INC.)third_quarter 2026 · $0.3 million
- Oct 20, 2026LobbyingLobbying report (ALSTON & BIRD LLP)third_quarter 2026 · $0.0 million
- Oct 19, 2026LobbyingLobbying report (CONTINENTAL STRATEGY, LLC)third_quarter 2026 · $0.0 million
- Sep 29, 2026Patent
- Sep 21, 2026Trademark
- Sep 15, 2026Patent
- Sep 15, 2026Patent
- Sep 14, 20268-KDirector or officer changeItem 5.02
- Sep 10, 20268-KDirector or officer changeItem 5.02
- Sep 8, 2026Patent
- Aug 25, 2026Patent
- Jul 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)second_quarter 2026 · $0.0 million
- Jul 20, 2026LobbyingLobbying report (DEXCOM, INC.)second_quarter 2026 · $0.4 million
- Jul 20, 2026LobbyingLobbying report (ALSTON & BIRD LLP)second_quarter 2026 · $0.0 million
- May 28, 20268-KShareholder vote resultsItem 5.07
- Mar 2, 20268-KDirector or officer changeItem 5.02
- Feb 26, 20268-KDirector or officer changeItem 5.02
- Feb 12, 202610-KAnnual report (10-K)1 risk factors added, 0 removed
- Jan 5, 2026Trademark
- Dec 22, 20258-KDirector or officer changeItem 5.02
- Oct 27, 20258-KDirector or officer changeItem 5.02
- Sep 18, 2025Trademark
- Sep 18, 2025Trademark
- Sep 16, 20258-KDirector or officer changeItem 5.02
- Jul 30, 20258-KDirector or officer changeItem 5.02
- May 13, 20258-KDirector or officer changeItem 5.02
- May 9, 20258-KShareholder vote resultsItem 5.07
- May 9, 20258-KDirector or officer changeItem 5.02
- May 9, 20258-KDirector or officer changeItem 5.02
- May 2, 20258-KDirector or officer changeItem 5.02
- Apr 4, 2025Trademark
- Mar 25, 20258-KAuditor changeItem 4.01
- Mar 10, 20258-KDirector or officer changeItem 5.02
- Feb 18, 202510-KAnnual report (10-K)0 risk factors added, 3 removed
- Dec 23, 20248-KMaterial agreement signedItem 1.01
- Feb 8, 202410-KAnnual report (10-K)2 risk factors added, 2 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Idexx Laboratories IDXX | $4.5B | $1.3B | Jun 30, 2026 |
| ResMed| RMD | $5.7B | $1.6B | Jun 30, 2026 |
| Steris STE | $6.0B | $0.9B | Jun 30, 2026 |
| Edwards Lifesciences EW | $6.5B | $1.4B | Jun 30, 2026 |
| Bruker BRKR | $3.5B | $0.1B | Jun 30, 2026 |
| Globus Medical GMED | $3.1B | $0.8B | Jun 30, 2026 |
| Insulet Corporation PODD | $3.0B | $0.3B | Jun 30, 2026 |
| Revvity RVTY | $2.9B | $0.6B | Jul 5, 2026 |